Sarepta Therapeutics (NASDAQ:SRPT) Upgraded to “Equal Weight” at Barclays

Sarepta Therapeutics (NASDAQ:SRPT) was upgraded by analysts at Barclays from an “underweight” rating to an “equal weight” rating in a report released on Tuesday, Marketbeat reports. The firm currently has a $22.00 target price on the biotechnology company’s stock. Barclays‘s price target points to a potential upside of 33.98% from the company’s current price.

Several other research analysts have also recently issued reports on SRPT. Jefferies Financial Group decreased their target price on shares of Sarepta Therapeutics from $40.00 to $35.00 and set a “buy” rating for the company in a report on Thursday, July 24th. Deutsche Bank Aktiengesellschaft reaffirmed a “hold” rating on shares of Sarepta Therapeutics in a report on Monday, July 21st. Evercore ISI cut shares of Sarepta Therapeutics from an “outperform” rating to an “inline” rating and set a $50.00 target price for the company. in a report on Thursday, May 8th. Mizuho restated a “neutral” rating and set a $14.00 price objective (down previously from $40.00) on shares of Sarepta Therapeutics in a research report on Monday, July 21st. Finally, BMO Capital Markets increased their price objective on shares of Sarepta Therapeutics from $25.00 to $50.00 and gave the company a “market perform” rating in a research report on Tuesday. Six equities research analysts have rated the stock with a sell rating, sixteen have given a hold rating and eight have given a buy rating to the stock. Based on data from MarketBeat, Sarepta Therapeutics has a consensus rating of “Hold” and an average target price of $49.12.

Sarepta Therapeutics Stock Down 2.0%

NASDAQ SRPT traded down $0.33 during trading hours on Tuesday, reaching $16.42. 14,128,350 shares of the company’s stock traded hands, compared to its average volume of 5,749,337. Sarepta Therapeutics has a 52-week low of $10.41 and a 52-week high of $145.00. The firm has a market cap of $1.61 billion, a PE ratio of -6.10 and a beta of 0.45. The firm has a 50-day simple moving average of $24.69 and a 200 day simple moving average of $62.20. The company has a debt-to-equity ratio of 1.00, a current ratio of 4.02 and a quick ratio of 2.46.

Sarepta Therapeutics (NASDAQ:SRPT) last released its quarterly earnings data on Tuesday, May 6th. The biotechnology company reported ($3.42) earnings per share for the quarter, missing analysts’ consensus estimates of $2.20 by ($5.62). The firm had revenue of $744.86 million for the quarter, compared to the consensus estimate of $685.75 million. Sarepta Therapeutics had a negative net margin of 11.12% and a negative return on equity of 14.88%. The firm’s revenue for the quarter was up 80.2% compared to the same quarter last year. During the same quarter in the prior year, the business posted $0.73 earnings per share. Sell-side analysts anticipate that Sarepta Therapeutics will post 2.67 EPS for the current fiscal year.

Institutional Trading of Sarepta Therapeutics

Several institutional investors and hedge funds have recently bought and sold shares of the business. Byrne Asset Management LLC acquired a new position in Sarepta Therapeutics in the 1st quarter valued at $30,000. Center for Financial Planning Inc. acquired a new stake in Sarepta Therapeutics in the 1st quarter valued at about $31,000. Ancora Advisors LLC lifted its holdings in Sarepta Therapeutics by 150.0% in the 1st quarter. Ancora Advisors LLC now owns 500 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 300 shares in the last quarter. Banque Transatlantique SA purchased a new position in Sarepta Therapeutics in the 1st quarter valued at about $44,000. Finally, Pandora Wealth Inc. purchased a new position in Sarepta Therapeutics in the 1st quarter valued at about $45,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.